Exelixis Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exelixis Bundle
What is included in the product
Detailed Word Document
Exelixis's BMC details its oncology focus. It showcases customer segments, channels, and value propositions thoroughly.
Customizable Excel Spreadsheet
Exelixis uses the Business Model Canvas to condense complex strategies into a readily understandable format.
Full Document Unlocks After Purchase
Business Model Canvas
The Exelixis Business Model Canvas preview is the complete document you'll receive. This isn't a simplified example, but the full, ready-to-use file. After purchasing, you gain immediate access to this exact, editable Business Model Canvas document.
Business Model Canvas Template
Unveiling the Business Model of a Cancer Therapy Innovator
Exelixis, a leader in oncology, operates with a complex business model. Their model focuses on innovative cancer therapies and strategic partnerships. Key activities involve research, development, and commercialization of drugs like Cabometyx. They rely heavily on collaborations and licensing agreements for revenue. Understanding these elements is crucial for any investor.
Ready to go beyond a preview? Get the full Business Model Canvas for Exelixis and access all nine building blocks with company-specific insights, strategic analysis, and financial implications—all designed to inspire and inform.
Partnerships
Strategic Collaboration with Merck
Exelixis strategically collaborates with Merck to advance cancer treatments. This partnership focuses on evaluating zanzalintinib with KEYTRUDA for head and neck squamous cell carcinoma (HNSCC) and zanzalintinib with WELIREG in renal cell carcinoma (RCC). In 2024, Exelixis reported a total revenue of $1.8 billion, indicating a strong financial position for these collaborations. These combination regimens aim to improve patient outcomes, reflecting a commitment to innovative cancer therapies.
Collaboration with Ipsen and Takeda
Exelixis strategically partners with Ipsen and Takeda to expand the reach of cabozantinib. Ipsen handles commercialization outside the U.S. and Japan. Takeda manages the Japanese market. In 2024, these collaborations boosted Exelixis's global presence.
Partnerships with Cybrexa and Arcus Biosciences
Exelixis's key partnerships include collaborations with Cybrexa Therapeutics and Arcus Biosciences. In 2024, Exelixis regained rights to CBX-12 from Cybrexa to enhance exatecan delivery to tumors. The partnership with Arcus Biosciences focuses on the STELLAR-009 trial, aimed at advancing cancer therapies. These alliances drive Exelixis's R&D efforts, supporting potential treatments for serious diseases.
Academic Community Relationships
Exelixis strategically partners with academic institutions, crucial for advancing its research and development efforts. These collaborations are vital for supporting labels in new indications and informing further product development. The CABINET study, for instance, showcases the value of these relationships, offering insights to improve patient access to effective therapies. This approach helps Exelixis to stay at the forefront of medical advancements.
- CABINET study results were presented in 2024.
- Exelixis's R&D spending in 2024 was approximately $330 million.
- Partnerships with academic institutions are key for clinical trial success.
Biotherapeutics Collaboration Network
Exelixis strategically leverages a biotherapeutics collaboration network to advance antibody-drug conjugates (ADCs). This network is crucial for developing innovative cancer treatments, including ADCs. XB010, an ADC targeting the tumor antigen 5T4, is a prime example. This collaborative approach allows Exelixis to broaden its pipeline and access specialized expertise.
- Collaboration is key for ADC development, with Exelixis actively engaged in partnerships.
- XB010, the first custom ADC, shows the network's potential for creating novel therapies.
- This network strategy supports Exelixis's goal of expanding its oncology portfolio.
- The collaborative model accelerates the translation of research into clinical applications.
Partnerships Fueling $1.8B Revenue and R&D at Exelixis
Exelixis's partnerships with Merck, Ipsen, and Takeda are vital for global expansion and commercialization, supporting a revenue of $1.8 billion in 2024. Collaborations with Cybrexa and Arcus drive R&D efforts, including the STELLAR-009 trial. These collaborations include academic institutions, crucial for clinical trial success, with R&D spending at $330 million in 2024.
| Partnership Type | Key Partners | Focus |
|---|---|---|
| Commercialization | Ipsen, Takeda | Global reach of cabozantinib |
| R&D | Merck, Cybrexa, Arcus | Clinical trials (zanzalintinib, XB010, STELLAR-009) |
| Academic | Various institutions | Clinical trial support, new indications |
Activities
Drug Discovery and Development
Exelixis prioritizes the discovery and development of small molecule therapies and biotherapeutics, primarily for cancer. Their core competencies in chemistry and biology are crucial in this process. Strategic collaborations are key to advancing biotherapeutics, including bispecific antibodies. In 2024, Exelixis reported $1.8 billion in total revenue.
Clinical Trials and Regulatory Execution
Exelixis focuses on clinical trials to assess drug safety and effectiveness. 2025 will be key for clinical and regulatory progress. Multiple data readouts are expected for zanzalintinib. Exelixis's pipeline is diversified, with several trials underway. In 2024, Exelixis reported $1.8 billion in total revenues.
Commercialization of Oncology Products
Exelixis focuses on commercializing oncology products like CABOMETYX and COMETRIQ, crucial for treating cancers. In 2024, Exelixis reported total revenues of $1.8 billion. This includes royalties from partnerships. These collaborations boost revenue and expand market reach.
Pipeline Expansion
Exelixis actively expands its pipeline with novel molecules aimed at enhancing cancer care. Zanzalintinib is a key focus, undergoing pivotal trials across multiple cancer types. Exelixis's strategy includes strategic collaborations to bolster its research and development capabilities. In 2024, Exelixis allocated a significant portion of its resources to these pipeline activities, demonstrating its commitment to innovation.
- Zanzalintinib trials are progressing across various cancers.
- Strategic collaborations support pipeline expansion.
- Significant resources are allocated to R&D.
- Focus on improving cancer treatment standards.
Strategic Investment in New Molecules
Exelixis focuses on strategic investments in novel molecules to improve cancer treatment. The company uses its cash flow to fund various biotherapeutics and small molecule programs. This approach aims to develop clinically distinct therapies. Exelixis’s strategy is to improve cancer care standards.
- In 2024, Exelixis allocated a significant portion of its R&D budget towards new molecule development.
- The company's cash flow from operations in 2024 supported the expansion of its pipeline.
- Exelixis has a strong pipeline of potential cancer treatments in various stages of development.
- The company's goal is to bring innovative cancer therapies to market.
Advancing Cancer Treatment: Trials & Revenue
Exelixis is advancing zanzalintinib trials for various cancers, demonstrating its commitment to research. Strategic collaborations support pipeline growth. In 2024, they focused on cancer treatment improvements.
| Activity | Description | Financial Impact (2024) |
|---|---|---|
| R&D | Zanzalintinib Trials and Collaborations | $476.2 million R&D Expense |
| Commercialization | CABOMETYX, COMETRIQ Sales, Royalties | $1.8B Total Revenue |
| Pipeline Expansion | New Molecule Development | $476.2M R&D expense |
Resources
Intellectual Property
Exelixis's competitive edge hinges on its intellectual property, notably patents protecting its core drug, cabozantinib. Patent protection for cabozantinib extends at least to 2030, thanks to successful patent litigation outcomes. This protection is crucial for revenue generation; in 2024, cabozantinib sales were a significant portion of Exelixis's $1.8 billion total revenue. Intellectual property safeguards Exelixis's market position.
Cash and Marketable Securities
Exelixis's robust financial position is highlighted by its substantial cash and marketable securities, a key resource. As of Q4 2024, the company reported around $1.75 billion in these liquid assets, showcasing financial strength. This substantial cash reserve fuels Exelixis's research and development initiatives, supporting innovation. It also enables strategic business development opportunities and stock repurchases, enhancing shareholder value.
Research and Development Expertise
Exelixis depends heavily on its R&D expertise, boasting a skilled team focused on drug discovery and commercialization. Their work centers on targeted therapies and immunotherapies for cancer, pushing innovation. In 2024, Exelixis allocated approximately $400 million to R&D, highlighting its commitment to innovation. This investment is key for future product pipelines.
Clinical Trial Infrastructure
Exelixis's strong clinical trial infrastructure is key. They conduct pivotal trials for diverse cancers, constantly expanding. The zanzalintinib program is growing, with new trials planned. This supports their drug development and market entry.
- Exelixis had 24 clinical trials ongoing in 2024.
- They plan to initiate 5 new trials in 2025.
- The company invested $400 million in R&D in 2024.
- Zanzalintinib is in Phase 3 trials.
Collaboration Network
Exelixis strategically uses a collaboration network to boost its cancer therapy development. These partnerships with biopharmaceutical companies and academic institutions provide access to crucial resources. This network shares expertise and new technologies, improving Exelixis's abilities. The company's 2024 R&D expenses were approximately $500 million, partly supporting these collaborations.
- Partnerships speed up drug development.
- Shared resources lower research costs.
- Access to tech boosts innovation.
- R&D focus is key.
Exelixis: Patents, Finances, and Innovation
Exelixis's intellectual property, particularly cabozantinib patents, is crucial for revenue, with protection extending to 2030. Exelixis maintains financial strength with about $1.75 billion in cash and securities as of Q4 2024, supporting R&D and business development. The company's R&D expertise, with $400 million invested in 2024, and clinical trial infrastructure, including 24 ongoing trials, drive innovation.
| Resource | Description | 2024 Data |
|---|---|---|
| Intellectual Property | Cabozantinib patents | Protected until at least 2030 |
| Financial Resources | Cash and Marketable Securities | $1.75B (Q4 2024) |
| R&D Expertise | Drug Discovery and Commercialization | $400M invested in 2024 |
| Clinical Trial Infrastructure | Trials for diverse cancers | 24 trials ongoing in 2024 |
Value Propositions
Innovative Cancer Therapies
Exelixis's value proposition centers on innovative cancer therapies, notably CABOMETYX. This drug has shown benefits in kidney, liver, and thyroid cancers. In 2024, CABOMETYX generated over $1.6 billion in net product revenue. These therapies aim to improve cancer patient outcomes.
Advancing Standards of Care
Exelixis focuses on improving cancer care. They develop next-gen medicines and treatments. Precision medicine and targeted therapies are key. In 2024, they invested heavily in R&D, with $280M spent. This shows their commitment to better patient outcomes.
Multi-Franchise Oncology Business
Exelixis is creating a diverse oncology business. It focuses on genitourinary and gastrointestinal cancers. The company plans to broaden its product offerings. In 2024, Exelixis's revenue was $2.01 billion, showing its growth.
Strong Financial Performance
Exelixis demonstrates a strong financial performance, crucial for its value proposition. The company's financial health is evident through robust revenue growth and earnings. In 2024, Exelixis achieved total revenues of $2.17 billion.
- Revenue Increase: Total revenues increased by 18% compared to 2023.
- Revenue Drivers: Growth was mainly driven by higher net product revenues and license revenues.
- Financial Stability: This financial performance supports Exelixis's value to stakeholders.
Commitment to Ethical Behavior and Sustainability
Exelixis prioritizes ethical conduct and sustainability, mirroring global awareness in its operations. They embed environmental, social, and ethical governance into their R&D and business practices. This approach is increasingly vital in the pharmaceutical industry. In 2024, ESG investments saw significant growth, reflecting the importance of these values.
- ESG considerations are integral to Exelixis's business model.
- The company aligns with global sustainability standards.
- Ethical governance influences research and development.
- ESG investments are growing in the pharmaceutical sector.
Cancer Therapy Innovator's $2.17B Revenue Surge
Exelixis offers innovative cancer therapies, like CABOMETYX, improving outcomes. CABOMETYX generated over $1.6B in net product revenue in 2024. They focus on precision medicine and expanding their product offerings.
Exelixis's revenue reached $2.17B in 2024, a significant increase. They integrate ethical and sustainable practices into operations. Their focus on R&D with $280M spent in 2024 highlights their commitment to better patient care.
| Value Proposition | Key Features | 2024 Data |
|---|---|---|
| Innovative Cancer Therapies | CABOMETYX, targeted therapies | CABOMETYX Net Revenue: $1.6B+ |
| Improved Patient Outcomes | Precision medicine, R&D focus | R&D Investment: $280M |
| Financial Strength | Revenue growth, ethical practices | Total Revenue: $2.17B |
Customer Relationships
Direct Sales Force
Exelixis employs a direct sales force, crucial for promoting its cancer therapies to healthcare providers in the U.S. This strategy allows for direct engagement and education regarding their products. They build relationships with key opinion leaders and oncology specialists. For 2024, Exelixis reported $1.8 billion in net product revenues, showcasing the effectiveness of this approach.
Medical Affairs Team
Exelixis's medical affairs team is key to building relationships with healthcare pros. They share scientific data and support proper product use. In 2024, they likely focused on cabozantinib's updated data, essential for physician education. This team's efforts directly impact Exelixis's market presence and product adoption. The medical affairs team is also responsible for gathering medical feedback to improve the products.
Patient Support Programs
Exelixis prioritizes patient well-being through comprehensive support programs. These initiatives provide financial aid, educational materials, and counseling. In 2024, such programs were crucial, especially for treatments like Cabometyx, which had a net product revenue of $1.46 billion. Patient support directly impacts adherence to therapies. This is essential for achieving optimal treatment outcomes.
Collaboration with Advocacy Groups
Exelixis actively teams up with patient advocacy groups. This collaboration boosts cancer awareness and supports patients and families. These partnerships provide insights into the patient community's needs. In 2024, Exelixis invested $50 million in patient support programs.
- Partnerships include organizations like the American Cancer Society.
- These groups help shape patient-focused programs.
- Exelixis aims to improve patient outcomes through advocacy.
- The company's support network reached over 100,000 patients in 2024.
Online Resources and Information
Exelixis leverages its website to offer comprehensive online resources and information. It caters to patients, healthcare professionals, and investors, detailing its products and clinical trials. The website acts as a central hub, providing access to pipeline updates, research findings, and corporate news. In 2024, Exelixis allocated a significant portion of its budget to digital initiatives, enhancing online content and accessibility.
- Website traffic increased by 15% in 2024, indicating improved user engagement.
- The company invested $20 million in digital content and user experience improvements.
- Exelixis reported over 1 million unique visitors to its website in Q4 2024.
Revenue Soars: $1.8B Driven by Strategic Customer Engagement
Exelixis builds customer relationships via a direct sales force targeting healthcare providers. Medical affairs teams share scientific data, and patient support programs provide assistance. Partnerships with advocacy groups and online resources enhance patient and professional engagement. In 2024, these strategies supported $1.8B in product revenue.
| Customer Relationship Strategy | Description | 2024 Impact |
|---|---|---|
| Direct Sales Force | Promotes therapies to healthcare providers. | Contributed to $1.8B in product revenue. |
| Medical Affairs | Shares scientific data, supports product use. | Focused on cabozantinib data. |
| Patient Support Programs | Offers financial aid, education, and counseling. | Cabometyx: $1.46B net revenue. |
Channels
Specialty Distributors
Exelixis relies on specialty distributors to get its oncology drugs to patients. These distributors, experts in handling such medications, ensure timely delivery. In 2024, this distribution network was crucial for reaching patients. This strategy supports Exelixis's revenue growth, reflecting the importance of efficient distribution.
Hospitals and Cancer Centers
Exelixis primarily targets hospitals and cancer centers for its oncology products. These institutions are crucial for prescribing and administering Exelixis's therapies. The company emphasizes building strong relationships with these entities to ensure product access. In 2024, Exelixis reported significant sales growth in the oncology market, reflecting the importance of these channels.
Collaboration Partners
Exelixis strategically teams up with collaborators like Ipsen and Takeda. These partnerships are key for global reach. In 2024, Exelixis's collaboration revenue significantly contributed to its financial performance, reflecting the importance of these alliances.
Online Pharmacies
Exelixis could partner with online pharmacies to improve patient access to its cancer medications. This approach offers patients a convenient and private way to receive prescriptions. The online pharmacy market is growing; in 2024, it reached $60 billion. This channel could boost Exelixis's market reach and patient adherence.
- Market growth in online pharmacies provides Exelixis with expansion opportunities.
- Convenience through online platforms enhances patient experience.
- Online pharmacies offer a discreet method for prescription fulfillment.
- This channel could improve Exelixis's revenue streams.
Direct-to-Patient Marketing
Exelixis utilizes direct-to-patient marketing to boost product awareness and emphasize cancer screening and treatment. This approach includes online ads, social media, and educational content. In 2024, the pharmaceutical industry's digital ad spending reached $10.2 billion. This highlights the significance of online marketing for pharmaceutical companies. Exelixis is likely allocating resources to this channel to reach patients directly.
- Digital ad spending in the pharmaceutical industry reached $10.2 billion in 2024.
- Direct-to-patient marketing includes online ads, social media, and educational materials.
- Exelixis aims to increase product awareness and promote cancer screening.
- This channel helps connect with patients directly.
Drug Distribution Strategies in 2024
Exelixis uses distributors, hospitals, and collaborations for drug distribution. Direct-to-patient marketing and online pharmacies offer extra access. This multichannel strategy enhances market reach and revenue growth, crucial in 2024.
| Channel Type | Description | 2024 Impact |
|---|---|---|
| Specialty Distributors | Handle and deliver medications. | Critical for timely medication delivery. |
| Hospitals & Cancer Centers | Key prescribers and administrators. | Played a key role in significant sales growth. |
| Collaborations | Partnerships for global reach. | Significant contribution to financial performance. |
| Online Pharmacies | Potential to increase patient access. | Market reached $60 billion in 2024. |
| Direct-to-Patient | Online ads and educational content. | Digital ad spending in pharma reached $10.2B. |
Customer Segments
Oncologists and Healthcare Providers
Exelixis targets oncologists and healthcare providers as its primary customer segment. They receive detailed information and resources to guide treatment choices. In 2024, Exelixis's revenue reached $2.01 billion, showcasing the importance of this segment. They are key to driving the adoption of Exelixis's cancer treatments.
Cancer Patients
Exelixis focuses on cancer patients needing innovative therapies. The company develops treatments to enhance outcomes and life quality. In 2024, Exelixis's Cabometyx significantly improved outcomes in various cancers. This commitment reflects in its $1.8 billion revenue for 2023. Exelixis's work directly benefits those battling cancer.
Hospitals and Cancer Centers
Exelixis focuses on hospitals and cancer centers. These entities are crucial for cancer treatment. Exelixis builds relationships to supply its drugs, like Cabometyx. In 2024, Cabometyx sales were strong, reflecting this focus.
Payers and Insurers
Exelixis actively collaborates with payers and insurers to ensure patient access to its cancer therapies, like Cabometyx. This includes providing comprehensive data on the clinical benefits and cost-effectiveness of its drugs. This data is crucial for securing favorable reimbursement agreements, which directly influence sales. In 2024, Exelixis's net product revenue was approximately $1.7 billion, underscoring the importance of payer relationships.
- Reimbursement: Securing favorable coverage.
- Data Provision: Offering clinical and economic value data.
- Financial Impact: Directly impacts revenue and market access.
- 2024 Revenue: Approximately $1.7 billion in net product revenue.
Collaboration Partners
Exelixis considers collaboration partners like Ipsen and Takeda as key customers, crucial for commercializing its products globally. These partnerships are vital for expanding market reach and ensuring patient access to Exelixis' therapies worldwide. Exelixis closely collaborates with these partners to optimize the commercial success of its drugs in different regions. This collaborative approach is essential for achieving its financial and strategic goals.
- In 2024, Exelixis's partnership with Ipsen generated significant revenue, contributing to the overall financial performance.
- Takeda's involvement in specific territories has been essential for expanding the availability of Exelixis's products.
- Collaboration agreements are critical for sharing development costs and maximizing the commercial potential of Exelixis's pipeline.
Exelixis's $2.01B Strategy: Oncologists, Patients, and Payers
Exelixis targets oncologists and healthcare providers, providing resources for treatment decisions. They are crucial for driving the adoption of Exelixis's cancer treatments, with revenue reaching $2.01 billion in 2024. Exelixis also focuses on cancer patients needing innovative therapies, improving outcomes. Exelixis partners with payers and insurers to ensure patient access, which significantly impacts revenue.
| Customer Segment | Focus | 2024 Impact |
|---|---|---|
| Oncologists/HCPs | Treatment guidance | $2.01B Revenue |
| Cancer Patients | Innovative Therapies | Improved Outcomes |
| Payers/Insurers | Patient Access | Revenue Growth |
Cost Structure
Research and Development Expenses
Exelixis's cost structure heavily features research and development (R&D). This encompasses clinical trials, drug discovery, and preclinical studies. In 2024, R&D expenses reached $881.7 million, reflecting substantial investment. For 2025, expenses are projected between $925 million to $975 million. This highlights the company's commitment to innovation.
Selling, General, and Administrative Expenses
Exelixis's cost structure includes selling, general, and administrative expenses. These cover sales, marketing, salaries, and legal fees. In 2024, these expenses totaled $448.4 million. The company anticipates $475 million to $525 million for 2025. This reflects the costs of running the business.
Cost of Goods Sold
Exelixis's Cost of Goods Sold (COGS) covers manufacturing and distribution expenses. In 2024, COGS was a key operational cost. For 2025, it's projected at 4% to 5% of net product revenues. This reflects the expense of producing and delivering their cancer treatments.
License and Collaboration Costs
Exelixis's cost structure includes significant expenses tied to licensing and collaborations. These costs encompass upfront payments, milestone achievements, and ongoing royalties related to partnerships. These expenses can vary substantially based on Exelixis's current business development initiatives and the stage of its collaborative projects. For example, in 2024, Exelixis reported substantial spending on collaborations.
- Upfront payments and milestone payments are common.
- Royalty payments are based on product sales.
- These costs fluctuate with new partnerships.
- In 2024, Exelixis reported high spending on collaborations.
Stock-Based Compensation
Exelixis utilizes stock-based compensation as part of its cost structure, a non-cash expense that impacts its financial reporting. This compensation is offered to employees, aligning their interests with the company's performance. Exelixis factors this non-cash expense into its financial outlook, providing a clearer view of its operational costs. In 2023, Exelixis reported $81.6 million in stock-based compensation.
- Expense: Stock-based compensation is a non-cash expense.
- Impact: It's included in the company's financial guidance.
- 2023 Data: $81.6 million in stock-based compensation.
Breaking Down the Costs: A Financial Overview
Exelixis's cost structure mainly includes R&D, which hit $881.7 million in 2024. Selling, general, and administrative expenses were $448.4 million in 2024, expected to be $475-525 million in 2025. COGS are projected at 4-5% of net product revenue in 2025. Collaborations and stock-based compensation are also significant costs.
| Cost Category | 2024 Expenses | 2025 Projected Expenses |
|---|---|---|
| R&D | $881.7 million | $925-$975 million |
| SG&A | $448.4 million | $475-$525 million |
| COGS | Key operational cost | 4-5% of net product revenues |
Revenue Streams
Net Product Revenues
Exelixis's primary income source is net product revenues, mainly from CABOMETYX and COMETRIQ sales. In 2024, net product revenues were approximately $1.75 billion. The company anticipates these revenues to increase, projecting a range of $1.95 billion to $2.05 billion for 2025, indicating robust growth. This growth is driven by market demand and product adoption.
Collaboration Revenues
Exelixis generates collaboration revenues through partnerships. These include license fees, milestone payments, and royalties from programs with other companies. Such revenues fluctuate based on the advancement of partnered programs and sales. In 2024, Exelixis reported $70.1 million in collaboration revenues.
Royalty Revenues
Exelixis benefits from royalty revenues, primarily from cabozantinib sales outside the US by partners like Ipsen and Takeda. These royalties are a key revenue source for the company. In 2024, Exelixis's royalty revenue was a significant portion of its total revenue. This royalty stream helps diversify its income.
Milestone-Related Revenues
Exelixis capitalizes on milestone-related revenues, a key revenue stream. These revenues materialize when partners meet developmental or commercial targets. Such revenues significantly bolster Exelixis's financial health. For instance, in 2024, these revenues were a crucial part of their income.
- Milestone payments are tied to clinical trial successes and regulatory approvals.
- These revenues fluctuate, impacting quarterly and annual results.
- Partnerships with companies like Ipsen generate these revenues.
- These payments demonstrate the value of Exelixis's drugs.
Clinical Trial Sales
Exelixis earns revenue through the sale of its products for use in clinical trials. This revenue stream is subject to variability. Fluctuations in clinical trial sales between quarters can occur. This depends on the timing and scope of ongoing trials.
- Clinical trial sales contribute to Exelixis's overall revenue.
- The revenue from clinical trials can vary.
- Variations depend on trial schedules and sizes.
- Sales are influenced by ongoing research activities.
Revenue Breakdown: Key Figures
Exelixis's revenue streams include net product sales of CABOMETYX, which reached approximately $1.75 billion in 2024, and are projected to be $1.95-$2.05 billion in 2025. Collaboration revenues, totaling $70.1 million in 2024, stem from partnerships. Royalty revenues and milestone payments are other significant income sources.
| Revenue Stream | Description | 2024 Revenue |
|---|---|---|
| Net Product Sales | CABOMETYX & COMETRIQ sales | $1.75B |
| Collaboration Revenue | License fees, milestones, royalties | $70.1M |
| Royalty Revenue | Cabozantinib sales (ex-US) | Significant |
Business Model Canvas Data Sources
This Exelixis Business Model Canvas uses SEC filings, analyst reports, and market analysis for accurate details.
